About Tregenesis Sciences
Tregenesis Sciences is a Healthcare company based in Hyderabad (India). It develops and markets medicines for gastrointestinal diseases through research and partnerships. It operates on a B2B model. Its Indian entity Tregenesis Sciences Private Limited reported revenue of ₹6.64 Cr. Tregenesis Sciences offers products and services including Mesagran, Benztre, Lyoflora, Xifatre, and Duofiber. Its focus areas include Pharmaceuticals, Gastroenterology, Digestive System Disorders and Inflammatory Bowel Diseases.
Company details
Tregenesis Sciences is a global pharmaceutical company focused on improving gastrointestinal health through research-driven innovation. They develop and market treatments for diseases like inflammatory bowel disease, ulcerative colitis, and Crohns, collaborating with healthcare professionals. Based in India, they emphasize sustainability, ethical conduct, and community partnerships to enhance patient care and access to medicines.
- Headquarters Hyderabad, India
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website tregenesissciences.com
- Legal Name Tregenesis Sciences Private Limited
- Date of Incorporation 23 Jun, 2016
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹6.64 Cr
FY 2024 · +35% YoY
- Net Profit₹15.2 Lakh
FY 2024 · 2% margin
- EBITDA₹17.8 Lakh
FY 2024 · 3% margin
Associated legal entities of Tregenesis Sciences
Tregenesis Sciences operates through Tregenesis Sciences Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Tregenesis Sciences Private Limited CIN U74999TG2016PTC110481 | Active | 23 Jun 2016 | Hyderabad, Telangana | ₹6.6 Cr | 21 | 2 | View details |
Products & Services of Tregenesis Sciences
Tregenesis Sciences offers a comprehensive portfolio of products and services, including Mesagran, Benztre, Lyoflora, Xifatre, and Duofiber.
Treatment for gastrointestinal inflammatory conditions
Therapy for digestive system disorders
Support for gut health and related issues
Medication targeting bowel diseases
Aid for gastrointestinal symptoms and management
Board of directors of Tregenesis Sciences Private Limited (Tregenesis Sciences)
Tregenesis Sciences Private Limited is the primary company behind Tregenesis Sciences. The board of Tregenesis Sciences Private Limited currently have 2 directors; the longest-serving is Rishu Choudhary, appointed in 2016. 1 earlier director has ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Rishu Choudhary DIN 07504459 | Director | 23 Jun 2016 | 10 yrs 4 mo | Tregenesis Sciences Private Limited |
| Ran Pal DIN 07505448 | Director | 23 Jun 2016 | 10 yrs 4 mo | Tregenesis Sciences Private Limited |
Financials of Tregenesis Sciences
Figures of Tregenesis Sciences Private Limited, the primary company behind Tregenesis Sciences, for FY 2024. Revenue was ₹6.64 Cr (+35% year on year). Net profit was ₹15.2 Lakh (2% margin). EBITDA was ₹17.8 Lakh (3% margin). Revenue has grown at a compounded annual rate of +42% over three years and +44% over five years.
- ₹6.64 CrRevenue · FY 2024 · +35% YoY
- ₹15.2 LakhNet profit · 2% margin
- ₹17.8 LakhEBITDA · 3% margin
- ₹30 LakhPaid-up capital
- 21Employees (provident fund records)
- +42%Revenue CAGR, 3 years
- +44%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Tregenesis Sciences Private Limited are on its company page.
Detailed financial statements for Tregenesis Sciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Tregenesis Sciences
Tregenesis Sciences is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
The primary company behind Tregenesis Sciences, Tregenesis Sciences Private Limited, reported revenue of ₹6.64 Cr for FY 2024, up 35% year on year.
Tregenesis Sciences is a global pharmaceutical company focused on improving gastrointestinal health through research-driven innovation. They develop and market treatments for diseases like inflammatory bowel disease, ulcerative colitis, and Crohns, collaborating with healthcare professionals. Based in India, they emphasize sustainability, ethical conduct, and community partnerships to enhance patient care and access to medicines.
Tregenesis Sciences offers Mesagran, Benztre, Lyoflora, Xifatre, and Duofiber.
Tregenesis Sciences operates through Tregenesis Sciences Private Limited.
The legal entities of Tregenesis Sciences currently have 2 directors, including Rishu Choudhary, Ran Pal.